Literature DB >> 10084500

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation.

S D Anker1, A J Coats.   

Abstract

Chronic heart failure (CHF) is a complex syndrome affecting many body systems. Body wasting (ie, cardiac cachexia) is a serious complication of CHF long known but little investigated. Although no specific diagnostic criteria have been established, we have suggested that cardiac cachexia be defined on the basis of the presence of documented nonintentional and nonedematous weight loss > 7.5% of the premorbid normal weight, occurring over a time period of > 6 months. Using this definition, 16% of an unselected CHF outpatient population was found to be cachectic. The cachectic state is predictive of impaired prognosis independently of age, functional disease classification, left ventricular ejection fraction, and peak oxygen consumption. The mortality in the cachectic cohort is 50% at 18 months. Analyzing body composition in detail, it has been found that patients with cardiac cachexia suffer from a general loss of fat tissue (ie, energy reserves), lean tissue (ie, skeletal muscle), and bone tissue (ie, osteoporosis). Cachectic CHF patients are weaker and fatigue earlier, which is due to both reduced skeletal muscle mass and impaired muscle quality. The pathophysiologic alterations leading to cardiac cachexia remain unclear, but initial cross-sectional studies have suggested that humoral neuroendocrine and immunologic abnormalities are linked, independently of established heart failure severity markers, to the presence of body wasting. Comparing the features of cachectic and noncachectic CHF patients with those of healthy control subjects, it is mainly the cachectic CHF patients who show raised plasma levels of epinephrine, norepinephrine, and cortisol; the highest plasma renin activity and aldosterone plasma concentrations; and the lowest plasma sodium level. Several studies have shown that cardiac cachexia is linked to raised plasma levels of tumor necrosis factor-ac. The degree of body wasting is strongly correlated with neurohormonal and immune abnormalities. The available evidence suggests that cardiac cachexia is a multifactorial neuroendocrine and metabolic disorder with a poor prognosis. A complex imbalance of different body systems may cause the development of body wasting.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084500     DOI: 10.1378/chest.115.3.836

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  60 in total

Review 1.  Clinical nutrition: 1. Protein-energy malnutrition in the inpatient.

Authors:  L J Hoffer
Journal:  CMAJ       Date:  2001-11-13       Impact factor: 8.262

Review 2.  Ventricular assist devices: pharmacological aspects of a mechanical therapy.

Authors:  O Wever-Pinzon; J Stehlik; A G Kfoury; J V Terrovitis; N A Diakos; C Charitos; D Y Li; S G Drakos
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

3.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

4.  Moderate physical exercise reduces parasitaemia and protects colonic myenteric neurons in mice infected with Trypanosoma cruzi.

Authors:  Neide M Moreira; Franciele d N Santos; Max Jean d O Toledo; Solange M F d Moraes; Eduardo J d A Araujo; Debora d M G Sant'Ana; Silvana M d Araujo
Journal:  Int J Exp Pathol       Date:  2013-11-01       Impact factor: 1.925

5.  The prognostic value of anemia in patients with diastolic heart failure.

Authors:  Faramarz Tehrani; Anita Phan; Ryan Morrissey; Christopher Chien; Asim Rafique; Ernst R Schwarz
Journal:  Tex Heart Inst J       Date:  2009

Review 6.  Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks.

Authors:  Simon S Wing; Stewart H Lecker; R Thomas Jagoe
Journal:  Crit Rev Clin Lab Sci       Date:  2011-06-24       Impact factor: 6.250

7.  Reduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placement.

Authors:  Christine J Chung; Christina Wu; Meaghan Jones; Tomoko S Kato; Tien T Dam; Raymond C Givens; Danielle L Templeton; Mathew S Maurer; Yoshifumi Naka; Hiroo Takayama; Donna M Mancini; P Christian Schulze
Journal:  J Card Fail       Date:  2014-02-22       Impact factor: 5.712

8.  Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure.

Authors:  Aline Regina Ruiz Lima; Paula Felippe Martinez; Katashi Okoshi; Daniele Mendes Guizoni; Leonardo A Mamede Zornoff; Dijon Henrique Salomé Campos; Sílvio Assis Oliveira; Camila Bonomo; Maeli Dal Pai-Silva; Marina Politi Okoshi
Journal:  Int J Exp Pathol       Date:  2009-12-03       Impact factor: 1.925

9.  Body mass index, change in body mass index, and survival in old and very old persons.

Authors:  Anna K Dahl; Elizabeth B Fauth; Marie Ernsth-Bravell; Linda B Hassing; Nilam Ram; Denis Gerstof
Journal:  J Am Geriatr Soc       Date:  2013-03-01       Impact factor: 5.562

10.  RhoA induction by functional overload and nandrolone decanoate administration in rat skeletal muscle.

Authors:  Joseph M McClung; Won J Lee; Raymond W Thompson; Larry L Lowe; James A Carson
Journal:  Pflugers Arch       Date:  2003-10-11       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.